AURKA and small cell lung carcinoma: The benefit of using epigenetic therapy versus taking the alternative approach of targeting the new dependencies of transformed variants (such as FGFR for mesenchymal variants or AURKA for Rb1-deficient, transformed SCLC) also needs to be clarified.